Orion Corp
KRX:271560
Orion Corp
Accrued Liabilities
Orion Corp
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orion Corp
KRX:271560
|
Accrued Liabilities
₩105.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
CJ CheilJedang Corp
KRX:097950
|
Accrued Liabilities
₩409.6B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
Ottogi Corp
KRX:007310
|
Accrued Liabilities
₩51.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
|
S
|
Samyang Foods Co Ltd
KRX:003230
|
Accrued Liabilities
₩10.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
22%
|
CAGR 10-Years
16%
|
|
|
Dongwon Industries Co Ltd
KRX:006040
|
Accrued Liabilities
₩312.5B
|
CAGR 3-Years
40%
|
CAGR 5-Years
26%
|
CAGR 10-Years
22%
|
|
|
Nongshim Co Ltd
KRX:004370
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Orion Corp
Glance View
Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.
See Also
What is Orion Corp's Accrued Liabilities?
Accrued Liabilities
105.8B
KRW
Based on the financial report for Dec 31, 2024, Orion Corp's Accrued Liabilities amounts to 105.8B KRW.
What is Orion Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
10%
Over the last year, the Accrued Liabilities growth was 29%. The average annual Accrued Liabilities growth rates for Orion Corp have been 19% over the past three years , 10% over the past five years .
You don't have any saved screeners yet